References
|
1. Louis D, More K, Oberoi S, Shah PS. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014;99:F325-31.
2. Zwiers C et al. Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev. 2018 Mar 18;3:CD003313. doi: 10.1002/14651858.CD003313.pub2. PubMed PMID:29551014
3. Cortey A, Elzaabi M, Waegemans T, Roch B, Aujard Y. [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis]. Arch Pediatr. 2014;21:976-83.
4. National Blood Authority (NBA). Patient Blood Management Guidelines: Module 6 – Neonatal and Paediatrics. NBA, Canberra, Australia. 2016.
5. American Academy of Pediatrics Subcommittee on H. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297-316.
6. NICE Guideline. Jaundice in newborn babies under 28 days. Clinical guideline Published: 19 May 2010 nice.org.uk/guidance/cg98
7. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2015:CD001239.
8. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013:CD000361.
9. Zifman E, Litmanovitz I, Segal G, Regev R, Watemberg N. Marked hypotonia in an infant of a mother with Devic disease. J Child Neurol. 2010;25:746-7.
10. O'Carroll P, Bertorini TE, Jacob G, Mitchell CW, Graff J. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis. J. 2009;11:69-71.
11. Tagher RJ, Baumann R, Desai N. Failure of intravenously administered immunoglobulin in the treatment of neonatal myasthenia gravis. J Pediatr. 1999;134:233-5.
12. Bassan H, Muhlbaur B, Tomer A, Spirer Z. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis. Pediatr Neurol. 1998;18:181-3.
13. Yen MH, Huang YC, Chen MC, Liu CC, Chiu NC, Lien R, Chang LY, Chiu CH, Tsao KC, Lin TY. Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration. J Clin Virol. 2015;64:92-6.
14. Whitington PF, Kelly S, Taylor SA, Nobrega S, Schreiber RA, Sokal EM, Hibbard JU. Antenatal Treatment with Intravenous Immunoglobulin to Prevent Gestational Alloimmune Liver Disease: Comparative Effectiveness of 14-Week versus 18-Week Initiation. Fetal Diagnosis and Therapy. 2018;43:218-25.
15. Lee SS, Lee CH, Kawada P, O'Loughlin E V, Magoffin A, Gaskin KJ, Stormon MO. Long term outcome of neonatal hemochromatosis: A review of two decades of experience. Journal of Gastroenterology and Hepatology (Australia). 2014;2):152.
16. Baruteau J, Heissat S, Broue P, Collardeau-Frachon S, Bouvier R, Fabre M, Debiec H, Ronco P, Uzan M, Narcy P, Cordier MP, Lachaux A, Lamireau T, Elleau C, Filet JP, Mitanchez D, Dupuy MP, Salaun JF, Odent S, Davison J, Debray D, Guigonis V. Transient neonatal liver disease after maternal antenatal intravenous IG infusions in gestational alloimmune liver disease associated with neonatal haemochromatosis. Journal of Pediatric Gastroenterology and Nutrition. 2014;59:629-35.
17. Taylor SA, Kelly S, Alonso EM, Whitington PF. The Effects of Gestational Alloimmune Liver Disease on Fetal and Infant Morbidity and Mortality. Journal of Pediatrics. 2018;196:123-8.
18. National Blood Authority Specialist Working Group for Haematology. Proposed changes to the criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition 2012. https://www.blood.gov.au/ accessed 13/06/2018.
19. Basta M, Branch DR. 7th International Immunoglobulin Conference: Mechanisms of action. Clin Exp Immunol. 2014;178 Suppl 1:87-8 and 111.
|
